Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month

Sep 24, 2024
1 min read

CEO Neil Torbett describes the SITESEEKER target ID platform that is the company's foundation. More color on individual programs will be disclosed at the upcoming Targeted Protein Degradation & Induced Proximity Symposium in October.

https://vimeo.com/1012453772

Recent Posts

See All

Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK

Barclays Miami: Janux's Founder & CEO David Campbell shares his thoughts on the company's PSMA x CD3 masked T-cell engager and discusses next steps. Plus, a CD19 for autoimmune

Barclays Miami: Teva CEO Richard Francis talks about the company's emphasis on developing innovative medicines - including two recent financial deals to speed up development of IL-15 and TL1A

Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight